Roche dives further into cancer cell therapy with Adaptimmun...

Roche has largely been a spectator on the side lines as other drugmakers have embraced cell therapies for cancer, but it has made a big play now, pledging $150 million upfront to an allianc

Health Innovators – Jo Brewer, Adaptimmune

In this episode of Health Innovators, pharmaphorum founder Paul Tunnah interviews Jo Brewer, senior vice president of allogeneic res

Astellas to work with Adaptimmune to develop 'off the shelf'...

Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer.

Q&A: Adaptimmune’s Elliot Norry on cell therapy

Dr Elliot Norry, inte

Change at the top at Adaptimmune as Noble stands down

Adaptimmune and GSK’s novel T-cell therapy works in solid tu...

Adaptimmune has more good news from its SPEAR T-cell therapy, yesterday unveiling encouraging early results in four patients with myxoid/round cell liposarcoma (MRCLS).